Skip to contentA
Aptevo Therapeutics Inc.
A
APVOAptevo Therapeutics Inc. Q2 2018 · 10-Q
Revenue$6.83M$6.83M+93.6% vs Q2 2017 Net Income-$13.14M-$13.14MN/M vs Q2 2017 EPS Diluted-$0.58-$0.58N/M vs Q2 2017 Operating Income-$12,444,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aptevo Therapeutics Inc. · CIK 1671584 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$16,100,000N/M Margins · derivedOperating margin-182.3%+233.2 pt vs Q2 2017
Net margin-192.6%+124.8 pt vs Q2 2017
ended Jun 30, 2018 · filed Aug 9, 2018 · 40 d after period end